Efficacy and safety of ramucirumab (RAM) for advanced hepatocellular carcinoma (HCC) with elevated alpha-fetoprotein (AFP) following first-line sorafenib across age subgroups in two global phase III trials (REACH and REACH-2)

Affiliation auteurs!!!! Error affiliation !!!!
TitreEfficacy and safety of ramucirumab (RAM) for advanced hepatocellular carcinoma (HCC) with elevated alpha-fetoprotein (AFP) following first-line sorafenib across age subgroups in two global phase III trials (REACH and REACH-2)
Type de publicationJournal Article
Year of Publication2019
AuteursKudo M., Galle P.R, Motomura K., Assenat E., Merle P., Brandi G., Daniele B., Okusaka T., Tomasek J., Borg C., Zagonel V., Morimoto M., Pracht M., Finn R.S, Llovet J., Homma G., Jen M-H., Shinozaki K., Yoshikawa R., Zhu A.X
JournalANNALS OF ONCOLOGY
Volume30
Pagination292
Date PublishedOCT
Type of ArticleMeeting Abstract
ISSN0923-7534